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Approximately 20%–25% of non-ST-segment elevation 
acute coronary syndrome (NSTE-ACS) patients have 
diabetes mellitus (DM) [1]. Patients with DM have worse 
outcomes due to higher rates of cardiovascular risk factors 
and coronary artery disease compared to non-diabetic 
patients [2]. The European and American guidelines rec-
ommend an invasive strategy with coronary angiography 
within 72 hours after presentation in patients with DM, 
whereas a selective invasive strategy remains reserved 
for lower risk NSTE-ACS patients [3,4]. These recom-
mendations are based on meta-analysis with less than 
9000 patients demonstrating a short- and medium-term 
reduction in MI and rehospitalisation at 1 year [5]. Long-
term outcomes of an early or selective invasive strategy 
in NSTE-ACS patients with DM remain underreported. 
Therefore we assessed 10-year outcomes of an early or 
selective invasive strategy in NSTE-ACS patients with 
or without DM.
Between July 2001 and August 2003, 1200 NSTE-ACS 
patients enrolled in the Invasive Versus Conservative 
Treatment in Unstable Coronary Syndromes (ICTUS) 
trial were randomly assigned to an early invasive (n = 
604, angiography <24–48 hours after randomisation) or a 
selective invasive strategy [n = 596, optimal (antianginal) 
medical therapy, angiography in case of refractory angina 
or inducible signs of ischemia during a pre-discharge 
ischemia detection test]. The study design of the ICTUS 
trial has been previously reported [6]. We collected 
and adjudicated 10-year follow-up of death, myocardial 
infarction (MI), and revascularisation through the Dutch 
population registry, phone calls, and patient records. The 
main outcome was 10-year death or spontaneous MI.
At baseline 166 patients (14%) were known with DM, of 
which 86 were randomised to an early invasive and 80 to 
a selective invasive strategy. Baseline characteristics were 
evenly distributed between patients in the early or selec-
tive invasive groups, regardless of the presence of DM. 
However, diabetic patients in the early invasive group 
were older compared to the selective invasive group [69.0 
years; interquartile range (IQR): 60.8–74.0 vs. 65.5 years; 
IQR: 55.3–72.0; P = 0.025]. Diabetic patients had higher 
rates prior MI (31% vs. 22%, hypertension (57% vs. 36%), 
ST-segment deviation (55% vs. 47%), and three-vessel 
and/or left main coronary artery disease (31% vs. 14%).
In-hospital angiography (75% vs. 77%, P = 0.77) and revas-
cularisation (56% vs. 58%, = 0.60) were similar in patients 
with and without DM. Among diabetic patients, in-hos-
pital angiography was performed in 97.7% in the early 
invasive group and 53.8% in the selective invasive group 
(P > 0.001). In-hospital revascularisation among patients 
with DM was 70.9% and 40.0% in the early and selective 
invasive groups respectively (P < 0.001). Most diabetics 
patients were treated with percutaneous coronary inter-
vention (early: 52.3% vs. selective: 30.0%; P = 0.004). 
In-hospital coronary artery bypass grafting performance in 
diabetic patients was not significantly different between 
the two groups (early: 18.6% vs. selective: 10.0%; 0.115).
Patients with DM had worse 10-year clinical outcomes 
compared to patients without DM, as is displayed in 
Fig.  1. Death or spontaneous MI at 10-year was sig-
nificantly higher in diabetic patients (51.7%) vs. non- 
diabetic patients (28.1%) [hazard ratio (HR): 2.26; 
95% confidence interval (CI): 1.77–2.88; P < 0.001]. 
All other events also were significantly higher among 
diabetic patients, with the exception of first revascu-
larisation and procedure-related MI. Among patients 
with DM, 10-year death or spontaneous MI was 58.5% 
in the early invasive group and 44.4% in the selec-
tive invasive group (HR: 1.44; 95% CI: 0.93–2.22; P = 
0.101) (Table 1). There were no significant differences 
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in other outcome measures in diabetic patients treated 
with an early or selective invasive strategy, except for 
a higher rate of revascularisation in the early invasive 
group [83.8% vs. 68.2% (HR: 2.12; 95% CI: 1.47–3.07; 
P < 0.001)]. There was no significant interaction 
between the presence of DM and treatment strategy 
for any of the study outcomes.
In a Cox proportional hazards model that adjusted for 
age, there was no significant difference in death or spon-
taneous MI at 10 years between diabetic patients treated 
with an early or selective invasive strategy (HR: 1.13; 
95% CI: 0.72–1.75; P = 0.603). Adjustment for age >65 
years (HR: 1.24; 95% CI: 0.80–1.92; P = 0.346) or age >70 
year demonstrated similar results (HR: 1.18; 95% CI: 
0.76–1.84; P = 0.463).
In this analysis of high-risk NSTE-ACS patients with 
elevated cardiac troponin, patients with DM had worse 
10-year outcomes compared to patients without DM. We 
could not demonstrate a statistically significant differ-
ence in 10-year death or spontaneous MI between the 
two strategies. This finding remained unchanged after 
adjustment for age. Our findings remain limited due to 
the small sample size, with only 166 diabetic patients. 
We did not record insulin-dependency of DM patients 
in our study and did not collect information on the 
development of DM during follow-up. Contemporary 
improvements such as drug-eluting stents, potent P2Y12 
inhibitors, and radial access were not in use at the time 
of inclusion. Our finding illustrate the continuing long-
term adverse effect of DM in NSTE-ACS. Although 
observed in other studies, non-cardiovascular death was 
also increased by two-fold in diabetics, suggesting uni-
dentified confounding. Research to identify and improve 
treatment strategies for diabetic NSTE-ACS patients 
are warranted.
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Fig. 1
Ten-year clinical outcomes of non-ST-segment elevation acute coronary syndrome patients with or without DM. CI, confidence interval; DM, diabe-
tes mellitus; HR, hazard ratio; MI, myocardial infarction.
Table 1 Kaplan–Meier estimates of 10-year clinical outcomes in non-ST-segment elevation acute coronary syndrome patients with or 
without diabetes mellitus
Patients with diabetes mellitus (n = 166) Patients without diabetes mellitus (n = 1034)
Interaction 
P valueEIS (n = 86) SIS (n = 80)
Hazard ratio  
(95% CI) P value EIS (n = 518) SIS (n = 516)
Hazard ratio  
(95% CI) P value
Death or spontaneous MI 49 (58.5) 35 (44.4) 1.44 (0.93–2.22) 0.101 150 (29.7) 133 (26.6) 1.12 (0.89–1.42) 0.328 0.316
Death or MI 50 (59.6) 36 (45.7) 1.46 (0.95–2.25) 0.081 172 (34.0) 141 (28.1) 1.26 (1.01–1.58) 0.041 0.561
All-cause death 42 (51.4) 30 (37.8) 1.50 (0.94–2.39) 0.093 114 (22.6) 108 (21.4) 1.06 (0.82–1.38) 0.664 0.202
Cardiovascular death 26 (36.9) 22 (28.8) 1.26 (0.71–2.22) 0.428 71 (14.8) 63 (13.0) 1.13 (0.81–1.59) 0.475 0.741
Non-cardiovascular death 16 (23.1) 8 (12.7) 2.15 (0.92–5.02) 0.078 43 (9.2) 45 (9.7) 0.96 (0.63–1.46) 0.849 0.093
MI 21 (27.0) 21 (28.1) 1.01 (0.55–1.84) 0.982 85 (17.6) 63 (12.9) 1.39 (1.00–1.93) 0.047 0.362
Spontaneous MI 19 (25.7) 20 (26.8) 0.94 (0.50–1.76) 0.839 56 (11.9) 52 (10.8) 1.07 (0.74–1.56) 0.716 0.747
Procedure-related MI 5 (5.8) 1 (1.3) 4.79 (0.56–41.03) 0.153 34 (6.6) 13 (2.5) 2.67 (1.41–5.07) 0.003 0.610
Revascularisation 68 (83.8) 51 (68.2) 2.12 (1.47–3.07) <0.001 428 (83.2) 306 (60.4) 2.62 (2.26–3.04) <0.001 0.261
CI, confidence interval; EIS = early invasive strategy; MI, myocardial infarction; SIS, selective invasive strategy.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Early or selective strategy in diabetic NSTE-ACS patients Hoedemaker et al. 97
Acknowledgements
This work was supported by the Interuniversity 
Cardiology Institute of the Netherlands (ICIN), the 
Working Group on Cardiovascular Research of the 
Netherlands (WCN), and educational grants from Eli 
Lilly, Sanofi/Synthelabo, Sanofi-Aventis, Pfizer, and 
Medtronic. Roche Diagnostics, the Netherlands, pro-
vided the reagents for Core Laboratory cardiac troponin 
T measurements.
Conflicts of interest
There are no conflicts of interest.
References
1 Damman P, Jernberg T, Lindahl B, de Winter RJ, Jeppsson A, Johanson 
P, et al. Invasive strategies and outcomes for non-ST-segment elevation 
acute coronary syndromes: a twelve-year experience from SWEDEHEART. 
Eurointervention 2016; 12:1108–1116.
2 Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of 
current treatment strategies and future directions. Diabetes Care 2009; 
32:531–540.
3 Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes 
DR Jr, et al. 2014 AHA/ACC guideline for the management of patients 
with non-ST-elevation acute coronary syndromes: a report of the American 
College of Cardiology/American Heart Association Task Force on practice 
guidelines. J Am Coll Cardiol 2014; 64:e139–e228.
4 Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al.; 
ESC Scientific Document Group. 2015 ESC guidelines for the manage-
ment of acute coronary syndromes in patients presenting without persistent 
ST-segment elevation: task force for the management of acute coronary 
syndromes in patients presenting without persistent ST-segment elevation of 
the European Society of Cardiology (ESC). Eur Heart J 2016; 37:267–315.
5 O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, 
et al. An invasive or conservative strategy in patients with diabetes mellitus 
and non-ST-segment elevation acute coronary syndromes: a collaborative 
meta-analysis of randomized trials. J Am Coll Cardiol 2012; 60:106–111.
6 de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, 
Bendermacher PE, et al.; Invasive versus Conservative Treatment in 
Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus 
selectively invasive management for acute coronary syndromes. N Engl J 
Med 2005; 353:1095–1104.
